Showing posts with label Ixabepilone. Show all posts
Showing posts with label Ixabepilone. Show all posts
Thursday, April 01, 2010
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary
Abstract
Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer.
add your opinions
doxorubicin
,
Ixabepilone
Subscribe to:
Posts
(
Atom
)